Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,102.44 -712.12 (-1.83%) Hang Seng
17,936.12 -5.66 (-0.03%) FTSE 100
8,127.23 -19.63 (-0.24%) Bitcoin USD
65,573.09 -949.66 (-1.43%) CMC Crypto 200
1,369.12 -19.04 (-1.37%)
Y-mAbs Therapeutics, Inc. (YMAB)
| Previous close | 11.91 |
| Open | 11.81 |
| Bid | 11.65 x 200 |
| Ask | 11.88 x 100 |
| Day's range | 11.67 - 11.96 |
| 52-week range | 4.60 - 20.90 |
| Volume | |
| Avg. volume | 365,971 |
| Market cap | 515.401M |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.49 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.14 |
Simply Wall St.With 43% stake, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) seems to have captured institutional investors' interest
Key Insights Significantly high institutional ownership implies Y-mAbs Therapeutics' stock price is sensitive to their...
GlobeNewswireY-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting
NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that preclinical GD2-SADA data will be presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2024 Annual Meeting taking place June 8 – 11, 2024, in Toronto, Can
- GlobeNewswire
Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer. “We are thrilled to welcome Dr. LaFrance to Y-mAbs,” Mike Rossi, President and Chief Executive Officer. “Nor
